🎉 Free to use until Sep 16, 2026 — try it out for our launch!
STOCKIQAISTOCKIQAI
עברית
S&P 5007,709.96▼ 0.18%
Dow Jones53,885.1▼ 0.85%
Nasdaq26,348.35▼ 0.06%
Russell 20003,001.55▼ 0.58%
Fear Index (VIX)15.15▼ 4.17%
TA-125₪4,032.47▲ 0.23%
S&P 5007,709.96▼ 0.18%
Dow Jones53,885.1▼ 0.85%
Nasdaq26,348.35▼ 0.06%
Russell 20003,001.55▼ 0.58%
Fear Index (VIX)15.15▼ 4.17%
TA-125₪4,032.47▲ 0.23%

TDOC

Teladoc Health Inc. Common Stock

Health Care · ·

$6.68

▼ $0.25 (-3.6%)

Market Cap

$1.21B

Day Range

$6.63 - $6.83

52-Week Range

$4.40 - $9.89

Beta

—

Next Earnings

27.10.2026

TDOC is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.

🏢 Similar Stocks in the Same Sector

ABBV

AbbVie Inc.

ABT

Abbott Laboratories

ACH

Accendra Health, Inc.

-0.9% (1Y)

Investor Score
46/ 100D+
🟡 Moderate

This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer

📈22FTechnical
💰30FFundamental
🚀62C+Growth
💎62C+Valuation
📰74BNews
🏦58CQuality
⚠️48D+Risk

Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%

🔍 Cross-Check

Overall Score

🟡 Mixed

Technical Trend

🔴 Bearish

Insiders

🔴 Bearish

✅ Why is the score relatively high?

  • 🟢 Estimated fair value: $25.12 vs. price $6.68 (+276.1%)
  • 🟢 Earnings per share (EPS) growth: 80.6%
  • 🟢 Net income growth: 80.0%
  • 🟢 Operating margin is stable or improving over time
  • 🟢 Current ratio: 2.77

⚠️ What's concerning?

  • 🔴 Operating margin: -10.4% (negative)
  • 🔴 Net margin: -7.9% (negative)
  • 🔴 ATR: 7.9% of price
  • 🔴 Return on equity (ROE): -14.5% (negative)
  • 🔴 Revenue growth (last year): -1.5%

🚦 Quality & Risk Checks

🟢 Operating margin stability🔴 Daily volatility (ATR)🟢 Liquidity risk

📰 News Trend

Based on real financial news (Finnhub)
🟢 Positive

Everyone's writing about Teladoc Health Inc. Common Stock. News trend score: 74. Reason: 9 of the last 20 articles are positive, versus 5 negative.

🔴 Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $7.5 — Benzinga🟢 Here are the top movers in Thursday's session. — ChartMill🟢 Let's uncover which stocks are experiencing notable gaps during today's session. — ChartMill

News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer

📈 Technical Analysis

Based on the last 251 trading days, calculated from real price data. Click an indicator for details and a chart.

🔴 Most indicators support a downtrend (1 bullish · 9 bearish · 1 neutral)

Conclusions

  • 🔴Price vs. SMA 50 — Price is below the 50-day average
  • 🟢Price vs. SMA 200 — Price is above the 200-day average
  • 🔴MACD — MACD histogram is negative — falling momentum
  • 🔴RSI — RSI 35.8 — weak/negative bias
  • 🔴Stochastic — %K 16.5 — oversold
  • 🔴ADX (trend strength) — ADX 37.6 — strong trend
  • 🔴Relative strength vs. S&P 500 — -0.7% over the last 3 months relative to the index
  • 🔴Bollinger Bands — Price is in the lower third of the Bollinger Bands (13%B) — weakness (chance of a recovery)
  • 🔴ROC (rate of change) — ROC 12 days: -28.2%
  • 🔴Parabolic SAR — Price is below the SAR point — downtrend
  • 🟡CMF (money flow) — CMF 20 days: -0.02

Wyckoff Method Analysis

A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.

Markup

The stock is in a clear uptrend with no defined trading range in the period examined.

High confidence

Evidence Behind This Read

  • 🟢Rising price trend — A 5.2% change over the last 50 days, with no defined trading range.

The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.

🎯 Trade Planning (M.A.E.E Framework)

Based on a mechanical trading method: market structure → value zone → ATR-based exit point. Not investment advice — a calculation tool only.

1️⃣ Market Structure

🟡 Range

The price is oscillating around the 200-day average with no clear direction — the method recommends great caution here (buying at the bottom of the range / selling at the top) or avoiding trading altogether.

2️⃣ Value Zone

🟡 Price far from value zone

The price is currently far from the 50-day average — the method recommends waiting for a "pullback" before entering, rather than chasing prices.

In a range, the method doesn't give a single directional stop point — the market currently lacks a clear direction, consider waiting for a breakout from the range.

💰 Financial Health

Profitability

Gross Margin

—

Operating Margin

-10.4%

Net Margin

-7.9%

EBITDA Margin

-10.4%

Efficiency

ROE

-14.5%

ROA

-7.0%

ROIC

—

EPS

-$1.14

Balance Sheet

Cash

$781.08M

Total Debt

—

Current Ratio

2.77

Debt/Equity

—

Conclusions

  • 🔴Operating margin — Operating margin: -10.4% (negative)
  • 🔴Net margin — Net margin: -7.9% (negative)
  • 🔴Return on equity (ROE) — Return on equity (ROE): -14.5% (negative)
  • 🔴Return on assets (ROA) — Return on assets (ROA): -7.0% — weak
  • 🟢Current ratio (liquidity) — Current ratio: 2.77

🚀 Growth

Revenue

Earnings per Share (EPS)

Net Income

Free Cash Flow (FCF)

Conclusions

  • 🔴Revenue growth (last year) — Revenue growth (last year): -1.5%
  • 🟢Earnings per share (EPS) growth — Earnings per share (EPS) growth: 80.6%
  • 🟡Free cash flow growth — Free cash flow growth: 0.9%
  • 🟢Net income growth — Net income growth: 80.0%

💎 Fair Value (Valuation)

Current Price

$6.68

Estimated Fair Value (DCF)

$25.12

Gap

+276.1%

🟢 Appears cheap relative to estimated value

Show all model (DCF) assumptions →

Year 1 Growth Rate

1.8%

Discount Rate (WACC)

9.0%

Terminal Growth Rate

2.5%

Projection Years

5

YearGrowth RateProjected FCFPresent Value
11.8%$290.53M$266.54M
22.0%$296.21M$249.31M
32.1%$302.54M$233.62M
42.3%$309.56M$219.30M
52.5%$317.29M$206.22M

Base FCF (last actual year)

$285.46M

Terminal Value

$5.00B

Present Value of Terminal Value

$3.25B

Enterprise Value

$4.43B

Net Debt

$0

Equity Value

$4.43B

*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.

Book Value per Share

$7.86

Tangible Book Value per Share (Tangible NAV)

-$1.10

Conclusions

  • 🟢DCF Fair Value — Estimated fair value: $25.12 vs. price $6.68 (+276.1%)
  • 🟡Tangible Net Asset Value (NAV) — NAV per share: -$1.10
  • 🟡P/E — P/E: -6.1

🕴️ Insider Trading

Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 11 sales out of the last 25 filings.

NameTransaction TypeDateSharesChangePrice
Anquillare Mark VGrant/Award from Employer3.8.202637,425+37,425—
Bliss KellyOpen Market Sale6.7.202684,878-2,500$9.50
Catapano Joseph RonaldOpen Market Sale2.7.202612,267-653$9.10
Bliss KellyOpen Market Sale1.7.202687,378-2,500$9.00
Catapano Joseph RonaldExercise of Derivative Securities1.7.202612,920+2,083—
Catapano Joseph RonaldExercise of Derivative Securities1.7.202610,418-2,083—
DIVITA CHARLES IIIOpen Market Sale11.6.2026414,622-18,074$6.94
DIVITA CHARLES IIIExercise of Derivative Securities10.6.2026393,536+3,642—
DIVITA CHARLES IIIExercise of Derivative Securities10.6.2026432,696+39,160—
DIVITA CHARLES IIIExercise of Derivative Securities10.6.202614,568-3,642—
DIVITA CHARLES IIIExercise of Derivative Securities10.6.2026156,643-39,160—
Rodrigues Fernando M.Open Market Sale3.6.20260-9,572$7.40
DIVITA CHARLES IIIOpen Market Sale2.6.2026389,894-19,132$7.63
Vandervoort Adam COpen Market Sale2.6.2026110,261-7,906$7.63
Catapano Joseph RonaldOpen Market Sale2.6.202610,837-284$7.63
Bliss KellyOpen Market Sale2.6.202692,378-7,679$7.63
Rodrigues Fernando M.Open Market Sale2.6.20269,572-5,677$7.63
Nueno CarlosOpen Market Sale2.6.202657,671-6,196$7.63
DIVITA CHARLES IIIExercise of Derivative Securities1.6.2026366,750+1,966—
DIVITA CHARLES IIIExercise of Derivative Securities1.6.2026409,026+42,276—
DIVITA CHARLES IIIExercise of Derivative Securities1.6.202613,761-1,966—
DIVITA CHARLES IIIExercise of Derivative Securities1.6.2026295,939-42,276—
Vandervoort Adam CExercise of Derivative Securities1.6.2026103,665+426—
Vandervoort Adam CExercise of Derivative Securities1.6.2026109,015+5,350—
Vandervoort Adam CExercise of Derivative Securities1.6.2026118,167+9,152—

📉 Short Interest

Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.

Monthly Trend — Open Short Interest

↑+2.3%

28,060,519 shares short as of 2026-07-15 · vs. 27,420,966 on 2026-06-30

Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.

Weekly Trend — Daily Short-Sale Activity

↓-21.8%

47.8% of trading volume this week was short selling, vs. 61.1% the prior week

Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.

📰 News & Sentiment

Sentiment based on basic keywords (not AI) — 9 positive, 6 neutral, 5 negative out of the last 20 articles.